234 related articles for article (PubMed ID: 24751730)
21. Clearance of invasive melanoma with topical imiquimod.
Moon SD; Spencer JM
J Drugs Dermatol; 2013 Jan; 12(1):107-8. PubMed ID: 23377337
[TBL] [Abstract][Full Text] [Related]
22. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.
Urosevic M; Dummer R; Conrad C; Beyeler M; Laine E; Burg G; Gilliet M
J Natl Cancer Inst; 2005 Aug; 97(15):1143-53. PubMed ID: 16077073
[TBL] [Abstract][Full Text] [Related]
23. Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis.
Majewski S; Marczak M; Mlynarczyk B; Benninghoff B; Jablonska S
Int J Dermatol; 2005 Jan; 44(1):14-9. PubMed ID: 15663652
[TBL] [Abstract][Full Text] [Related]
24. Regression of internal melanoma metastases following application of topical imiquimod to overlying skin.
Miller AK; Dusing R; Meggison A; Aires D
J Drugs Dermatol; 2011 Mar; 10(3):302-5. PubMed ID: 21369648
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of keratinocyte proliferation by phospholipid-conjugates of a TLR7 ligand in a Myc-induced hyperplastic actinic keratosis model in the absence of systemic side effects.
Crain B; Yao S; Keophilaone V; Promessi V; Kang M; Barberis A; Maj R; Mura E; Passini N; Holldack J; Ochoa R; Cottam HB; Carson DA; Hayashi T
Eur J Dermatol; 2013; 23(5):618-28. PubMed ID: 24225049
[TBL] [Abstract][Full Text] [Related]
26. ACTIBIND, a T2 RNase, competes with angiogenin and inhibits human melanoma growth, angiogenesis, and metastasis.
Schwartz B; Shoseyov O; Melnikova VO; McCarty M; Leslie M; Roiz L; Smirnoff P; Hu GF; Lev D; Bar-Eli M
Cancer Res; 2007 Jun; 67(11):5258-66. PubMed ID: 17545605
[TBL] [Abstract][Full Text] [Related]
27. Imiquimod Accelerated Antitumor Response by Targeting Lysosome Adaptation in Skin Cancer Cells.
Chang SH; Wu CY; Chuang KC; Huang SW; Li ZY; Wang ST; Lai ZL; Chang CC; Chen YJ; Wong TW; Kao JK; Shieh JJ
J Invest Dermatol; 2021 Sep; 141(9):2219-2228.e8. PubMed ID: 33744296
[TBL] [Abstract][Full Text] [Related]
28. Mediators of Inflammation in Topical Therapy of Skin Cancers.
Voiculescu VM; Lisievici CV; Lupu M; Vajaitu C; Draghici CC; Popa AV; Solomon I; Sebe TI; Constantin MM; Caruntu C
Mediators Inflamm; 2019; 2019():8369690. PubMed ID: 30766448
[TBL] [Abstract][Full Text] [Related]
29. IRF-2 haploinsufficiency causes enhanced imiquimod-induced psoriasis-like skin inflammation.
Kawaguchi M; Oka T; Sugaya M; Suga H; Kimura T; Morimura S; Fujita H; Sato S
J Dermatol Sci; 2018 Apr; 90(1):35-45. PubMed ID: 29305258
[TBL] [Abstract][Full Text] [Related]
30. Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts.
Orecchia P; Conte R; Balza E; Pietra G; Mingari MC; Carnemolla B
Oncotarget; 2015 Nov; 6(35):37426-42. PubMed ID: 26460958
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment of persistent melanoma in situ with 5% imiquimod cream.
Muñoz CM; Sánchez JL; Martín-García RF
Dermatol Surg; 2004 Dec; 30(12 Pt 2):1543-5. PubMed ID: 15606836
[TBL] [Abstract][Full Text] [Related]
32. Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors.
Xiong Z; Ohlfest JR
J Immunother; 2011 Apr; 34(3):264-9. PubMed ID: 21389872
[TBL] [Abstract][Full Text] [Related]
33. Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil.
Florin V; Desmedt E; Vercambre-Darras S; Mortier L
Invest New Drugs; 2012 Aug; 30(4):1641-5. PubMed ID: 21748297
[TBL] [Abstract][Full Text] [Related]
34. Imiquimod Increases Cutaneous VEGF Expression in Imiquimod-induced Psoriatic Mouse Model.
Wu HH; Xie WL; Zhao YK; Liu JH; Luo DQ
Curr Vasc Pharmacol; 2016; 14(3):275-9. PubMed ID: 26733387
[TBL] [Abstract][Full Text] [Related]
35. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS
Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291
[TBL] [Abstract][Full Text] [Related]
36. Combined treatment with intratumoral injection of dendritic cells and topical application of imiquimod for murine melanoma.
Lee JR; Shin JH; Park JH; Song SU; Choi GS
Clin Exp Dermatol; 2007 Sep; 32(5):541-9. PubMed ID: 17553061
[TBL] [Abstract][Full Text] [Related]
37. pDC Activation by TLR7/8 Ligand CL097 Compared to TLR7 Ligand IMQ or TLR9 Ligand CpG.
Wu J; Li S; Li T; Lv X; Zhang M; Zang G; Qi C; Liu YJ; Xu L; Chen J
J Immunol Res; 2019; 2019():1749803. PubMed ID: 31093508
[TBL] [Abstract][Full Text] [Related]
38. Combretastatin A4 Nanoparticles Combined with Hypoxia-Sensitive Imiquimod: A New Paradigm for the Modulation of Host Immunological Responses during Cancer Treatment.
Shen N; Wu J; Yang C; Yu H; Yang S; Li T; Chen J; Tang Z; Chen X
Nano Lett; 2019 Nov; 19(11):8021-8031. PubMed ID: 31558024
[TBL] [Abstract][Full Text] [Related]
39. Selective hemangioma cell dysfunction and apoptosis triggered by in vitro treatment with imiquimod.
Rocco R; Alegre N; Pozner R; Wainstok R; Gazzaniga S
Toxicol Lett; 2018 May; 288():82-88. PubMed ID: 29410238
[TBL] [Abstract][Full Text] [Related]
40. Imiquimod - Its role in the treatment of cutaneous malignancies.
Bubna AK
Indian J Pharmacol; 2015; 47(4):354-9. PubMed ID: 26288465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
